[go: up one dir, main page]

WO2004058353A3 - Therapeutic use of selective noradrenaline reuptake inhibitors - Google Patents

Therapeutic use of selective noradrenaline reuptake inhibitors Download PDF

Info

Publication number
WO2004058353A3
WO2004058353A3 PCT/GB2003/005693 GB0305693W WO2004058353A3 WO 2004058353 A3 WO2004058353 A3 WO 2004058353A3 GB 0305693 W GB0305693 W GB 0305693W WO 2004058353 A3 WO2004058353 A3 WO 2004058353A3
Authority
WO
WIPO (PCT)
Prior art keywords
reuptake inhibitors
noradrenaline reuptake
therapeutic use
selective noradrenaline
selective
Prior art date
Application number
PCT/GB2003/005693
Other languages
French (fr)
Other versions
WO2004058353A2 (en
Inventor
John Gary Montana
Original Assignee
Amedis Pharm Ltd
John Gary Montana
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0230135A external-priority patent/GB0230135D0/en
Priority claimed from GB0316203A external-priority patent/GB0316203D0/en
Application filed by Amedis Pharm Ltd, John Gary Montana filed Critical Amedis Pharm Ltd
Priority to AU2003290363A priority Critical patent/AU2003290363A1/en
Publication of WO2004058353A2 publication Critical patent/WO2004058353A2/en
Publication of WO2004058353A3 publication Critical patent/WO2004058353A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Selective noradrenaline reuptake inhibitors are used in the treatment of nausea, emesis and related conditions, e.g. as caused by opiates or by chemotherapy.
PCT/GB2003/005693 2002-12-24 2003-12-23 Therapeutic use of selective noradrenaline reuptake inhibitors WO2004058353A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003290363A AU2003290363A1 (en) 2002-12-24 2003-12-23 Therapeutic use of selective noradrenaline reuptake inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0230135A GB0230135D0 (en) 2002-12-24 2002-12-24 Compounds and their uses
GB0230135.6 2002-12-24
GB0316203A GB0316203D0 (en) 2003-07-10 2003-07-10 Compounds and their use
GB0316203.9 2003-07-10

Publications (2)

Publication Number Publication Date
WO2004058353A2 WO2004058353A2 (en) 2004-07-15
WO2004058353A3 true WO2004058353A3 (en) 2004-09-23

Family

ID=32683993

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/005693 WO2004058353A2 (en) 2002-12-24 2003-12-23 Therapeutic use of selective noradrenaline reuptake inhibitors

Country Status (2)

Country Link
AU (1) AU2003290363A1 (en)
WO (1) WO2004058353A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094786B2 (en) 2003-01-13 2006-08-22 Dynogen Pharmaceuticals, Inc. Method of treating nausea, vomiting, retching or any combination thereof
US7470690B2 (en) 2002-07-10 2008-12-30 Dynogen Pharmaceuticals, Inc. 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D)pyrimidine in the treatment of functional bowel disorder
US7659394B2 (en) 2004-04-30 2010-02-09 Pfizer Inc Substituted morpholine compounds for the treatment of central nervous system disorders

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE614616A (en) * 1961-03-03 1962-09-03 Geigy Ag J R Process for the preparation of dibenzoazepine compounds
EP0319061A1 (en) * 1987-11-28 1989-06-07 Akzo N.V. Medicament with antiemetic action
WO1998050044A1 (en) * 1997-05-07 1998-11-12 Algos Pharmaceutical Corporation Composition and method combining an antidepressant with an nmda receptor antagonist, for treating neuropathic pain
WO1999016769A1 (en) * 1997-09-26 1999-04-08 Monash University Resolution of optically-active compounds
US6034091A (en) * 1993-03-02 2000-03-07 John S. Nagle Method for treating emotional or mental illness and emotional or mental illness concomitant with seizures
WO2001062236A2 (en) * 2000-02-24 2001-08-30 Pharmacia & Upjohn Company New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent
WO2002043652A2 (en) * 2000-11-29 2002-06-06 Ramot At Tel-Aviv University Ltd. Anti-proliferative drugs
WO2002053140A2 (en) * 2001-01-02 2002-07-11 Pharmacia & Upjohn Company New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
WO2002076461A1 (en) * 2001-03-26 2002-10-03 Serdar Murat Dursun Combination of reboxetine and citalopram

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE614616A (en) * 1961-03-03 1962-09-03 Geigy Ag J R Process for the preparation of dibenzoazepine compounds
EP0319061A1 (en) * 1987-11-28 1989-06-07 Akzo N.V. Medicament with antiemetic action
US6034091A (en) * 1993-03-02 2000-03-07 John S. Nagle Method for treating emotional or mental illness and emotional or mental illness concomitant with seizures
WO1998050044A1 (en) * 1997-05-07 1998-11-12 Algos Pharmaceutical Corporation Composition and method combining an antidepressant with an nmda receptor antagonist, for treating neuropathic pain
WO1999016769A1 (en) * 1997-09-26 1999-04-08 Monash University Resolution of optically-active compounds
WO2001062236A2 (en) * 2000-02-24 2001-08-30 Pharmacia & Upjohn Company New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent
WO2002043652A2 (en) * 2000-11-29 2002-06-06 Ramot At Tel-Aviv University Ltd. Anti-proliferative drugs
WO2002053140A2 (en) * 2001-01-02 2002-07-11 Pharmacia & Upjohn Company New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
WO2002076461A1 (en) * 2001-03-26 2002-10-03 Serdar Murat Dursun Combination of reboxetine and citalopram

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
BLACKBURN T P ET AL: "Effects of viloxazine, its optical isomers and its major metabolites on biogenic amine uptake mechanisms in vitro and in vivo", EUROPEAN JOURNAL OF PHARMACOLOGY 1978 NETHERLANDS, vol. 52, no. 3-4, 1978, pages 367 - 374, XP001197258 *
BOLDEN-WATSON C ET AL: "Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes.", LIFE SCIENCES. 1993, vol. 52, no. 12, 1993, pages 1023 - 1029, XP001197330, ISSN: 0024-3205 *
FRAZER A: "Norepinephrine involvement in antidepressant action", 2000, JOURNAL OF CLINICAL PSYCHIATRY 2000 UNITED STATES, VOL. 61, NR. SUPPL. 10, PAGE(S) 25-30, ISSN: 0160-6689, XP008032989 *
FREDRIKSON M ET AL: "Delayed chemotherapy-induced nausea is augmented by high levels of endogenous noradrenaline.", BRITISH JOURNAL OF CANCER. OCT 1994, vol. 70, no. 4, October 1994 (1994-10-01), pages 642 - 645, XP008032984, ISSN: 0007-0920 *
GUPTA Y K ET AL: "Involvement of 5-HT1A and 5-HT2 receptor in cisplatin induced emesis in dogs.", INDIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, (2002 OCT) 46 (4) 463-7. JOURNAL CODE: 0374707. ISSN: 0019-5499., October 2002 (2002-10-01), XP008032799 *
HOLLAND J C ET AL: "A CONTROLLED TRIAL OF FLUOXETINE AND DESIPRAMINE IN DEPRESSED WOMED WITH ADVANCED CANCER", PSYCHO-ONCOLOGY, WILEY, CHICHESTER, GB, vol. 7, no. 4, July 1998 (1998-07-01), pages 291 - 300, XP008028709, ISSN: 1057-9249 *
KILOH L.G. ET AL: "A double blind comparative trial of viloxazine and amitriptyline in patients suffering from endogenous depression.", AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 13/4 (357-360). CODEN: ANZPBQ, 1979, XP008032797 *
KIMMEL H L ET AL: "Opioid receptor agonists and antagonists alter GBR12909-induced turning in the rat", EUROPEAN JOURNAL OF PHARMACOLOGY 19 FEB 1998 NETHERLANDS, vol. 343, no. 2-3, 19 February 1998 (1998-02-19), pages 119 - 127, XP001197319, ISSN: 0014-2999 *
PAWLOWSKI L ET AL: "EFFECTS OF ANTIDEPRESSANT DRUGS, SELECTIVE NORADRENALINE- OR 5-HYDROXYTRYPTAMINE UPTAKE INHIBITORS, ON APOMORPHINE-INDUCED HYPOTHERMIA IN MICE", PSYCHOPHARMACOLOGY, SPRINGER VERLAG, BERLIN, DE, vol. 88, no. 2, 1986, pages 240 - 246, XP009027103, ISSN: 0033-3158 *
PRAKASH C ET AL: "CYCLIC VOMITING SYNDROME IN ADULTS: CLINICAL FEATURES AND RESPONSE TO TRICYCLIC ANTIDEPRESSANTS", AMERICAN JOURNAL OF GASTROENTEROLOGY, NEW YORK, NY, US, vol. 94, no. 10, 1999, pages 2855 - 2860, XP001189009, ISSN: 0002-9270 *
PRAKASH C ET AL: "TRICYCLIC ANTIDEPRESSANTS FOR FUNCTIONAL NAUSEA AND VOMITING CLINICAL OUTCOME IN 37 PATIENTS", DIGESTIVE DISEASES AND SCIENCES, PLENUM PUBLISHING CO, US, vol. 43, no. 9, September 1998 (1998-09-01), pages 1951 - 1956, XP008028464, ISSN: 0163-2116 *
PRELUSKY, DAN B. ET AL: "The efficacy of various classes of anti- emetics in preventing deoxynivalenol-induced vomiting in swine", NATURAL TOXINS , 1(5), 296-302 CODEN: NATOEE; ISSN: 1056-9014, 1993, XP008032795 *
PYTHON A ET AL: "Effects of nisoxetine, a selective noradrenaline transporter blocker, on sleep in rats", PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR 1997 UNITED STATES, vol. 58, no. 2, 1997, pages 369 - 372, XP001197322, ISSN: 0091-3057 *
ROSS S B ET AL: "Tricyclic antidepressant agents. II. Effect of oral administration on the uptake of 3-H-noradrenaline and 14-C-5-hydroxytryptamine in slices of the midbrain-hypothalamus region of the rat.", ACTA PHARMACOLOGICA ET TOXICOLOGICA. 1975, vol. 36, no. 5, 1975, pages 395 - 408, XP008033046, ISSN: 0001-6683 *
SAWHNEY M S ET AL: "TRICYCLIC ANTIDEPRESSANTS FOR PERSISTENT OR RECURRENT VOMITING IN DIABETIC PATIENTS", GASTROENTEROLOGY, W.B.SAUNDERS COMPANY, PHILADELPHIA, US, vol. 120, no. 5, SUPPL 1, 20 May 2001 (2001-05-20), pages A243, XP008028462, ISSN: 0016-5085 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7470690B2 (en) 2002-07-10 2008-12-30 Dynogen Pharmaceuticals, Inc. 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D)pyrimidine in the treatment of functional bowel disorder
US7094786B2 (en) 2003-01-13 2006-08-22 Dynogen Pharmaceuticals, Inc. Method of treating nausea, vomiting, retching or any combination thereof
US7659394B2 (en) 2004-04-30 2010-02-09 Pfizer Inc Substituted morpholine compounds for the treatment of central nervous system disorders

Also Published As

Publication number Publication date
AU2003290363A8 (en) 2004-07-22
AU2003290363A1 (en) 2004-07-22
WO2004058353A2 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
WO2008051197A3 (en) Small-molecule botulinum toxin inhibitors
EG25011A (en) Amino-piperidin-1-yl-xanthines, the production thereof and the use of the same as medicaments.
WO2004037176A3 (en) Quinazolinones and derivatives thereof as factor xa inhibitors
WO2007076423A3 (en) INHIBITORS OF Akt ACTIVITY
WO2007014930A3 (en) Polyammonium/polysiloxane copolymers
WO2003048081A3 (en) Glycinamides as factor xa inhibitors
AU2003272285A1 (en) Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
AU2003265853A1 (en) Hedgehog antagonists, methods and uses related thereto
WO2007019439A3 (en) Block copolymer compositions and uses thereof
ZA200502247B (en) Selected CGRP antagonists, method for production and use thereof as medicament.
MXPA03008807A (en) Cyclopropylindole derivatives as selective serotonin reuptake inhibitors.
AP2005003467A0 (en) N-pyrrolidin-3-YL-amide derivatives as serotonin and noradrenaline reuptake inhibitors.
DK1670458T3 (en) 1-Amino-2-oxy-substituted tetrahydronaphthalane derivatives, processes for their preparation and their use as antiphlogistics
WO2005044093A3 (en) Delta-9- the treatment of multiple sclerosis
WO2006118884A3 (en) Drug delivery devices and related components, systems and methods
AU2002228317A1 (en) Benz-1,3-azole derivatives and their uses as heparanase inhibitors
MX2007002470A (en) Substituted phenylaminothiazoles and use thereof.
WO2004103283A3 (en) Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage
WO2005118831A3 (en) Polymeric compositions and related methods of use
WO2005032490A3 (en) Cyclic diamines and derivatives as factor xa inhibitors
WO2005013911A3 (en) Protective and therapeutic uses for tocotrienols
WO2008157563A3 (en) Deuterium-enriched clopidogrel
WO2007076320A3 (en) Compounds
UA83203C2 (en) Thiazol-(bi)cycloalkyl-carboxanilides and their use for fighting against undesirable microorganisms
NO20052557D0 (en) Morpholine derivatives for use as dopamine agonists in the treatment of, inter alia, sexual dysfunction.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP